Invitation Homes, Inc. INVH 深 沪
已收盘 04-02 16:00:00 美东时间
25.55
+0.700
+2.82%
华盛通- 最 高25.65
- 今 开24.85
- 成交量 505.02万股
- 最 低 24.79
- 昨 收 24.85
- 总市值 155.70亿
- 52周最高 34.619
- 市盈率 静 42.49
- 换手率 0.83%
- 52周最低 23.95
- 委 比 28.62%
- 总股本 6.09亿
- 历史最高 41.00
- 量 比 0.76
- 振 幅 3.46%
- 历史最低 9.71
- 每 手 1
- 风险率 2.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shares of homebuilders and housing-related stocks are trading higher as Treasury yields retract following President Trump's suspension of U.S. strikes on Iran's power and energy infrastructure for five days.
Shares of homebuilders and housing-related stocks are trading higher as Treasur...
03-24 00:19
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Mizuho Maintains Neutral on Invitation Homes, Lowers Price Target to $26
Mizuho analyst Haendel St. Juste maintains Invitation Homes (NYSE:INVH) with a Neutral and lowers the price target from $27 to $26.
03-13 20:59
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
The Analyst Verdict: Invitation Homes In The Eyes Of 15 Experts
Providing a diverse range of perspectives from bullish to bearish, 15 analysts ...
03-10 03:01
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Wells Fargo Maintains Equal-Weight on Invitation Homes, Lowers Price Target to $28
Wells Fargo analyst James Feldman maintains Invitation Homes (NYSE:INVH) with a Equal-Weight and lowers the price target from $31 to $28.
03-06 00:47
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Raymond James Downgrades Invitation Homes to Market Perform
Raymond James analyst Buck Horne downgrades Invitation Homes (NYSE:INVH) from Outperform to Market Perform.
02-28 02:04
